
Study shows 1 in 7 patients switch back to Humira after moving to biosimilars post-formulary changes
A new study analyzing nearly 68,000 US patients found that adoption of adalimumab biosimilars increased significantly after formulary changes, but over 16% of those who switched from Humira reverted back to the original drug. The research highlights ...

